Dolcanatide

Drug Profile

Dolcanatide

Alternative Names: SP 333

Latest Information Update: 06 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synergy Pharmaceuticals Inc
  • Class Anti-inflammatories; Peptide hormones
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation
  • Phase I Ulcerative colitis

Most Recent Events

  • 16 Feb 2016 Phase II development for Constipation is ongoing in USA (PO) (Synergy Pipeline, February 2016)
  • 18 Dec 2014 Synergy Pharmaceuticals completes a phase II trial in Constipation in USA
  • 19 Nov 2014 Phase-I clinical trials in Ulcerative colitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top